ArticleNature2020
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 1 pooled it
16.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
238 citing papers in PubMed, 1 synthesis or guideline pooled it, 351 citations in OpenAlex.
- Engineering cytokines for cancer immunotherapy: a systematic review.Frontiers in immunology · 2023Pooled it
- Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis.Signal transduction and targeted therapy · 2025Trial
- Article
- Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review).International journal of molecular medicine · 2026Review
- Bone targeted microenvironment actuated engineered exosomes for precision therapy of IBD associated bone loss.Bioactive materials · 2026Article
- Anti-CTLA-4 antibody potentiates the antitumor effect of armed oncolytic virus OVM18 via enhancing intratumoral IL-18R1Journal for immunotherapy of cancer · 2026Article
- Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy.Cell death and differentiation · 2026Article
- Article
- Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma.Cancer research · 2026Article
- Interleukin-18 armours antitumour immune effectors.Nature reviews. Immunology · 2026Review
- Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.Journal for immunotherapy of cancer · 2026Article
- Caspase-1 boosts immunotherapeutic efficacy via induction of CD8Science China. Life sciences · 2026Article
- IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response.Journal for immunotherapy of cancer · 2026Article
- ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy.Protein & cell · 2026Article
- NK cell cytotoxicity is transiently enhanced during acute malaria and modulated by the host microenvironment.JCI insight · 2026Article
- Advances in Cancer Immunotherapy for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A Viral-Host Immunogenetic Interaction Model in Hodgkin Lymphoma: Co-Association of HHV-6B Infection and IL-18 rs1946518 Polymorphism.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Mannose-binding lectin 2 secreted by hepatocellular carcinoma cells recruits and activates natural killer cells to reshape an immune-activated microenvironment.PLoS biology · 2026Article
- Hepatocyte estrogen-related receptor α modulates a gluconeogenic-epigenetic crosstalk counteracting MASLD/MASH progression.Experimental & molecular medicine · 2026Article
- Spatial instruction of tissue immunity.ImmunoHorizons · 2026Review
178 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 4 institutions in 2 countries.
Ting Zhou *Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-8783-8380
William Damsky *Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
Orr-El Weizman *Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Meaghan K McGearyDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-8505-7158
K Patricia HartmannDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Connor E RosenDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2442-3676
Suzanne FischerDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Ruaidhri JacksonDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Richard A FlavellDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-4461-0778
Jun WangDepartment of Pathology, New York University Langone Medical Center, New York, NY, USA.
Miguel F SanmamedDepartment of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
Marcus W BosenbergDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA.
Aaron M RingDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, USA. aaron.ring@yale.edu.ORCID http://orcid.org/0000-0003-3699-2446
Yale University · USClinica Universidad de Navarra · ESHoward Hughes Medical Institute · USNYU Langone Health · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI RUTH HALABAN · 2006 to 2026
$43.9MTumor Assessment CoreP01CA128814 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI STERN, DAVID F · 2009 to 2020
$19.1MCytokine immunotherapies for melanomaU01CA233096 · NCI · YALE UNIVERSITY · PI BOSENBERG, MARCUS W · 2019 to 2019
$3.8MPredoctoral Training Program in VirologyT32AI055403 · NIAID · YALE UNIVERSITY · PI KUMAR, PRITI, MOTHES, WALTHER H · 2003 to 2024
$3.6MUncoupling pleiotropy in the LIGHT/HVEM/LTBetaR signaling networkDP5OD023088 · OD · YALE UNIVERSITY · PI RING, AARON MICHAEL · 2016 to 2020
$2.1MNCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA128814NCI NIH HHS P50 CA121974NCI NIH HHS U01 CA233096NIAID NIH HHS T32 AI055403NIH HHS DP5 OD023088NIH HHS S10RR026992-0110
Abstract
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, but they have only modest efficacy and limited tolerability
Indexed as
ImmunotherapyAnimalsCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHepatocyte Nuclear Factor 1-alphaHistocompatibility Antigens Class IHumansIntercellular Signaling Peptides and ProteinsInterleukin-18Kaplan-Meier EstimateKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMaleMiceNeoplasmsHepatocyte Nuclear Factor 1-alphaHistocompatibility Antigens Class IHNF1A protein, humanIntercellular Signaling Peptides and ProteinsInterleukin-18interleukin-18 binding proteinReceptors, Interleukin-18
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.